Laser Caps for Men's Hair Loss: What the Trials Show and What FDA Clearance Means
Low-level laser caps and combs beat sham devices in small randomized trials in men. They are FDA-cleared, not FDA-approved, which means they were judged equivalent to devices already on the market. Finasteride and minoxidil have larger, longer trials behind them.
By Kymata Health Editorial Published Last checked
We earn a commission if you buy through links on this page. It never changes our grades or rankings. How we make money →
This guide
Men's Hair Loss- Question
- Do laser caps work for male pattern hair loss, and how do they compare with minoxidil and finasteride?
- Sources
- 14 cited
- Quick answers
- 3 questions
- Clinician review
- None; sources cited inline
Key takeaways
5 points- In a 44-man sham-controlled trial of a 655 nm laser helmet, hair counts rose about 67% from baseline vs about 28% with the sham over 16 weeks3.
- In laser-comb trials in men, terminal hair density rose by 18 to 26 hairs per cm² over 26 weeks vs 2 to 9 with sham devices4.
- FDA clearance through 510(k) means a device was found substantially equivalent to one already on the market; Kiierr's 2018 clearance cited no new clinical data12.
- Finasteride has 5-year placebo-controlled data in men9; we found no trial comparing a laser cap head to head with finasteride or minoxidil.
- Two 2025 meta-analyses disagree on whether adding a laser to topical minoxidil helps1011.
What a laser cap does
Laser caps and combs shine low-power red light, around 650 nm, on the scalp. This is low-level laser therapy (also called photobiomodulation), not the high-energy lasers used for hair removal. Kiierr's caps, for example, use class 3R diode lasers of 5 mW or less at 650 nm, and its cleared regimen is 30 minutes every other day for an initial 16 weeks1.
They are sold for androgenetic alopecia, the common pattern hair loss driven by hormones and genes. They are not meant for sudden or patchy hair loss, which needs a diagnosis first; the minoxidil label gives the same warning12.
What the trials in men show
The evidence comes from small sham-controlled trials:
- Helmet trial (2013): 44 men aged 18 to 48 with Norwood IIa-V hair loss used a 655 nm laser-and-LED helmet or an identical-looking sham every other day for 16 weeks. Hair counts in a small marked area rose 67.2% in the active group vs 28.4% with sham (P = 0.001); no adverse events were reported3. The helmet's maker, Apira Science, funded the trial, and some authors reported consulting fees or an ownership interest in the company3.
- Laser comb trials (2014): 128 men and 141 women were randomized to a laser comb or a sham three times a week for 26 weeks. In men, terminal hair density rose 18.4 to 25.7 hairs per cm² with the comb vs 1.6 to 9.4 with sham; no serious adverse events were reported, and 25 men were lost to follow-up4. Lexington International, which makes the HairMax comb, partly funded the trials and supplied the devices, two authors reported fees from it, and 94.7% of participants were white4.
- Pooled data: a 2017 meta-analysis found laser therapy, 5% and 2% minoxidil and 1 mg finasteride all beat placebo in men, with high heterogeneity between studies5. A 2021 meta-analysis of 7 double-blind trials of home-use devices found a large standardized increase in hair density vs sham, across both comb and helmet designs6.
FDA cleared vs FDA approved
Finasteride 1 mg (Propecia) and topical minoxidil are FDA-approved drugs for male pattern hair loss912. Laser caps reach the market through a 510(k), in which FDA decides whether a device is substantially equivalent, meaning as safe and effective, to a legally marketed predicate device; that order clears it for sale2.
Kiierr's 272 and 148 laser caps were cleared on Sept. 5, 2018 (K181878) to promote hair growth in men with Norwood-Hamilton IIa-V and women with Ludwig-Savin I-II androgenetic alopecia, in Fitzpatrick skin types I-IV1. Its summary states that no clinical performance data were produced for the submission, because the caps are the same private-label device as the predicate1. The HairMax LaserComb was cleared in January 20077.
So clearance tells you the device matches an earlier one in design and intended use. It does not show that one brand outperforms another, or that a laser cap matches a drug. Our laser cap and red light hat review checks every partner device against the FDA database.
How lasers compare with minoxidil and finasteride
No trial we found compared a laser cap head to head with finasteride or minoxidil, so any ranking is indirect. The drug trials are larger and longer:
- Finasteride 1 mg: in two 1-year trials of 1,553 men, hair counts in a 5.1 cm² area were 107 hairs higher than placebo at 1 year and 138 at 2 years in trials led by Merck researchers8; the label reports a 277-hair difference at 5 years9.
- Topical minoxidil 5%: in a 48-week trial of 393 men funded by Pharmacia, then the maker of Rogaine, 5% beat 2% and placebo, with about 45% more regrowth than 2%13.
- A 2022 network meta-analysis of drug trials in men found 1 mg finasteride gave a larger gain in terminal hair count at 48 weeks than topical minoxidil 5% (26.2 hairs per cm²)14.
- Adding a laser to minoxidil: one 2025 meta-analysis of 4 studies found no added benefit10; another of 7 trials found 6.62 more hairs per cm² with the combination11.
Safety, cost of commitment, and who should not rely on one
Short trials reported no adverse events in the helmet study and no serious ones with the laser comb34. The bigger risk is opportunity cost: a cap needs about 16 weeks of every-other-day sessions before you can judge it1, and the trials ran only 16 to 26 weeks; the laser-comb authors called for studies of long-term effects4.
The clearance covers Norwood IIa-V and skin types I-IV1; more advanced baldness and darker skin types V-VI fall outside what the clearance covers. Get a diagnosis first if hair loss is sudden, patchy or comes with scalp redness or pain12. If you have a light-sensitive skin condition or take a medicine that makes skin sensitive to light, ask a dermatologist before using one; the trials enrolled healthy adults34.
Where to buy
Kiierr
Paid links · we earn a commissionLaser caps (148 and 272 diodes) cleared by the FDA in 2018 to promote hair growth in men with Norwood-Hamilton IIa-V and women with Ludwig-Savin I-II pattern hair loss, in skin types I-IV. Clearance is not a head-to-head comparison with finasteride or minoxidil.
See Kiierr laser caps (paid link, opens in new tab)
Quick answers
Questions
3 answersIs Kiierr FDA-approved?
No. Kiierr's caps are FDA-cleared through the 510(k) pathway (K181878, 2018), which found them substantially equivalent to an existing laser cap12.
More in Men's Hair Loss
Keep reading
5 pages- Men's Hair Loss hubEvery guide, regulatory notes and sources
- Finasteride for Men's Hair Loss: What 5 Years of Trials Show and the Side Effects on the FDA Label
- Minoxidil for Men: Topical Foam or Solution vs Low-Dose Pills, by the Trials and the Labels
- Dutasteride vs Finasteride for Men's Hair Loss: What the Head-to-Head Trials Show, and the Safety Trade-Offs
- Rosemary Oil vs Minoxidil for Men's Hair Loss: What One Small Trial Shows and What It Doesn't
Keep reading: Testosterone (TRT) and men's hormones
Testosterone (TRT) and men's hormones: every pageMen's hormone telehealth comparedBrowse all topics
- Previous in this topicMen's Hair Loss: Finasteride, Minoxidil and Laser Caps, by the EvidenceFinasteride and minoxidil are the two FDA-approved drugs for male pattern hair loss, with the largest and longest trials.
- Next in this topicFinasteride for Men's Hair Loss: What 5 Years of Trials Show and the Side Effects on the FDA LabelFinasteride 1 mg slowed hair loss and regrew hair in placebo-controlled trials lasting up to 5 years.
- Pumpkin Seed Oil and Saw Palmetto for Hair Loss: What the Small Trials Show, and How They Stack Up Against FinasterideBoth are sold as natural DHT blockers for thinning hair.
- Pumpkin seed oilPumpkin seed oil is pressed from Cucurbita seeds and sold in capsules for hair thinning and urinary symptoms.
- Does Creatine Cause Hair Loss? The One Study Behind the Fear, and the Trial That Finally Checked HairA 2009 study of 20 rugby players launched a thousand forum threads.
References
Every study and document cited in this guide, numbered as in the text.
Sources
14 sources- 1510(k) Premarket Notification K181878: Kiierr 272 and 148 Laser (decision letter, indications and summary). U.S. Food and Drug Administration, 2018.
- 2Premarket Notification 510(k). U.S. Food and Drug Administration, 2024.
- 3The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers Surg Med, 2013. PMID 24078483
- 4Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol, 2014. PMID 24474647
- 5The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol, 2017. PMID 28396101
- 6A Systematic Review and Meta-analysis of Randomized Controlled Trials of United States Food and Drug Administration-Approved, Home-use, Low-Level Light/Laser Therapy Devices for Pattern Hair Loss: Device Design and Technology. J Clin Aesthet Dermatol, 2021. PMID 34980962
- 7510(k) Premarket Notification K060305: HairMax LaserComb. U.S. Food and Drug Administration, 2007.
- 8Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol, 1998. PMID 9777765
- 9PROPECIA (finasteride) tablets: prescribing information (revised 07/2022). U.S. Food and Drug Administration, 2022.
- 10Comparative efficacy of minoxidil alone versus minoxidil combined with low-level laser therapy in the treatment of androgenic alopecia: a systematic review and meta-analysis. J Dermatolog Treat, 2025. PMID 39828269
- 11Comparative efficacy and safety of low-level laser therapy and topical Minoxidil combination vs. topical Minoxidil monotherapy in androgenetic alopecia management: a systematic review and meta-analysis of randomized controlled trials. Lasers Med Sci, 2025. PMID 40826200
- 12Men's ROGAINE Extra Strength (5% minoxidil) topical solution: Drug Facts label. U.S. Food and Drug Administration, 2015.
- 13A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol, 2002. PMID 12196747
- 14Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol, 2022. PMID 35107565
Dietary supplements are not intended to diagnose, treat, cure or prevent any disease, and these statements have not been evaluated by the FDA. Prescription options need a licensed clinician. Talk to your clinician or pharmacist before starting anything new, especially if you take prescription medicines, are pregnant or breastfeeding.